Epstein J B, Wong F L
British Columbia Cancer Agency, Vancouver, Canada.
Int J Radiat Oncol Biol Phys. 1994 Feb 1;28(3):693-8. doi: 10.1016/0360-3016(94)90195-3.
The purpose of this study was to assess the value of sucralfate suspension in prevention of oral mucositis and for reduction of oral pain in patients who develop mucositis during radiation therapy.
The study was a double-blind, placebo-controlled, randomized prospective trial of a sucralfate suspension in the prevention and management of oral mucositis during radiation therapy. Oral mucositis was assessed using a quantitative scale and symptoms were assessed using visual analogue scales. The statistical model was developed to detect a 40% reduction in mucositis.
No statistically significant reduction in mucositis was seen. Early during radiation therapy less oral pain was reported in the sucralfate group, but as treatment progressed all patients experienced pain. Patients in the sucralfate group were prescribed topical and systemic analgesics later in the course of radiation therapy.
Prophylactic oral rinsing with sucralfate did not prevent oral ulcerative mucositis. Sucralfate may reduce the experience of pain during radiation therapy.
本研究旨在评估硫糖铝混悬液在预防放疗期间口腔黏膜炎以及减轻已发生黏膜炎患者口腔疼痛方面的价值。
本研究是一项关于硫糖铝混悬液预防和治疗放疗期间口腔黏膜炎的双盲、安慰剂对照、随机前瞻性试验。采用定量量表评估口腔黏膜炎,并使用视觉模拟量表评估症状。建立统计模型以检测黏膜炎减少40%的情况。
未观察到黏膜炎有统计学意义的减轻。放疗早期,硫糖铝组报告的口腔疼痛较少,但随着治疗进展,所有患者均出现疼痛。硫糖铝组患者在放疗后期使用了局部和全身镇痛药。
硫糖铝预防性口腔冲洗不能预防口腔溃疡性黏膜炎。硫糖铝可能减轻放疗期间的疼痛体验。